XOWNA® for Coronary Microvascular Dysfunction (CMD)
XOWNA® (CLBS16) is an experimental regenerative medicine that is currently being studied in a Phase 2b study (the “FREEDOM trial”) taking place in the United States for the treatment of CMD.
CLBS12 (HONEDRA® in Japan) for Critical Limb Ischemia (CLI)
HONEDRA® is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of CLI and Buerger’s disease by improving blood flow in the affected limb. CLBS12 has been granted orphan drug status in the United States by the Food and Drug Administration.
Learn more about our CD34+ technology
ESCaPE-CMD Patient Testimonial Video
Our proprietary CD34+ cell therapy platform has generated a multi-product development pipeline with the potential to provide curative therapies to people in need.
Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction
CD34+ Cell Therapy Significantly Reduces Adverse Cardiac Events, Health Care Expenditures, and Mortality in Patients with Refractory Angina
Testing for Coronary Microvascular Dysfunction
Autologous CD34+ Cell Therapy for Ischemic Tissue Repair
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Join Our Team
Our mission is to discover, develop and deliver innovative therapeutics in areas of unmet medical need that improve patient lives. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.